

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

RAJYA SABHA
UNSTARRED QUESTION NO.182
TO BE ANSWERED ON 22nd July 2025

Promotion of domestic manufacturing of KSMs/DIs/APIs

182 Shri Ratanjit Pratap Narain Singh:

Will the Minister of **Chemicals and Fertilizers** be pleased to state:

- (a) the detailed data on the number of beneficiaries under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates (DIs) and active pharmaceutical ingredients (APIs) in the country;
- (b) the detailed impact of the scheme in reducing imports of KSMs/DIs/APIs in 2024;
- (c) the steps taken to increase awareness of the scheme; and
- (d) whether Government plans to increase the target segments' products in the future, and if so, the details thereof?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS
(SMT. ANUPRIYA PATEL)**

(a): Under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India, 48 projects have been approved. Details in respect of applicants/beneficiaries under the scheme are at Annexure.

(b): The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source. Products notified and approved under the scheme prior to commencement of production under the PLI scheme were primarily imported. As of December 2024, against an investment commitment of ₹3,938.5 crore over the period of six years, investment of ₹4,254 crore has already been made under the scheme. As a result of the scheme, cumulative sales of ₹1,556 crore have been reported over the period from the beginning of the scheme till December 2024, including exports of ₹412 crore, thereby avoiding imports worth ₹1,144 crore and creating domestic manufacturing capacity for 25 identified KSMs/DIs/APIs.

(c): Number of measures were taken to enhance awareness and encourage participation in the scheme at the time of the launch of the scheme and various rounds of invitation of applications under it, including the following:

- (i) Conducting of webinars and stakeholder consultation meetings with industry associations and potential applicants;

- (ii) Issuing of press releases, detailed guidelines, clarifications in the form of frequently asked questions (FAQs) and answers thereto and scheme notifications on official websites;
- (iii) Regular outreach through social media campaigns;
- (iv) Provision of dedicated helpdesk support and query resolution mechanisms through the scheme portal; and
- (v) Issue of press releases and hosting of the same on government websites.

(d): No such plan is currently under consideration.

Annexure

Annexure referred to in the reply to Rajya Sabha Unstarred Q. No. 182 for answer on 22.7.2025, raised by Shri Ratanjit Pratap Narain Singh, regarding promotion of domestic manufacturing of KSMs/DIs/APIs

Details regarding applicants/beneficiaries under the PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs in India

S. No.	Name of the applicant	Approved product
1.	Lyfius Pharma Pvt. Ltd.	Penicillin G
2.	Karnataka Antibiotics and Pharmaceuticals Ltd.	7 ACA
3.	Kinvan Pvt. Ltd.	Clavulanic Acid
4.	Orchid Bio-Pharma Ltd.	7 ACA
5.	Macleods Pharmaceutical Ltd.	Rifampicin
6.	Natural Biogenex Pvt. Ltd.	Betamethasone
7.	Natural Biogenex Pvt. Ltd.	Dexamethasone
8.	Natural Biogenex Pvt. Ltd.	Prednisolone
9.	SymbiotecPharmalab Pvt. Ltd.	Prednisolone
10.	Emmennar Pharma Pvt. Ltd.	1,1 Cyclohexane Diacetic Acid (CDA)
11.	Granules India Ltd.	Dicyandiamide (DCDA)
12.	Hindys Lab Pvt. Ltd.	1,1 Cyclohexane Diacetic Acid (CDA)
13.	Meghmani LLP	Para Amino Phenol
14.	Sadhana Nitro Chem Ltd.	Para Amino Phenol
15.	Alta Laboratories Ltd.	Aspirin
16.	Amoli Organics Pvt. Ltd.	Diclofenac sodium
17.	Anasia Lab Pvt. Ltd.	Losartan
18.	Anasia Lab Pvt. Ltd.	Olmesartan
19.	Andhra Organics Ltd.	Olmesartan
20.	Andhra Organics Ltd.	Sulfadiazine
21.	Andhra Organics Ltd.	Telmisartan
22.	Aviran Pharmachem Pvt. Ltd.	Artesunate
23.	Centrient Pharmaceuticals India Pvt. Ltd.	Atorvastatin
24.	Dasami Lab Pvt. Ltd.	Carbamazepine
25.	Dasami Lab Pvt. Ltd.	Oxcarbazepine
26.	Global Pharma Healthcare Pvt. Ltd.	Ofloxacin
27.	Globela Industries Pvt. Ltd	Norfloxacin
28.	Globela Industries Pvt. Ltd	Ofloxacin
29.	Hazelo Lab Pvt. Ltd.	Vitamin B6
30.	Hetero Drugs Ltd.	Carbidopa
31.	Hetero Drugs Ltd.	Levodopa
32.	Hetero Drugs Ltd.	Levofloxacin
33.	Hetero Drugs Ltd.	Oxcarbazepine
34.	Hindys Lab Pvt. Ltd.	Acyclovir

35.	Honour Lab Ltd.	Levetiracetam
36.	Honour Lab Ltd.	Lopinavir
37.	Honour Lab Ltd.	Valsartan
38.	Honour Lab Ltd.	Vitamin B6
39.	K. P. Manish Global Ingredients Pvt. Ltd.	Artesunate
40.	Kreative Actives Pvt. Ltd.	Diclofenac sodium
41.	Lifetech Sciences	Ritonavir
42.	MSN Life Sciences Pvt. Ltd.	Levofloxacin
43.	Rajasthan Antibiotics Ltd.	Meropenem
44.	RMC Performance Chemicals Pvt. Ltd.	Aspirin
45.	Sudarshan Pharma Industries Ltd.	Vitamin B1
46.	Sudarshan Pharma Industries Ltd.	Vitamin B6
47.	Vital Laboratories Pvt. Ltd.	Levofloxacin
48.	Vital Laboratories Pvt. Ltd.	Ofloxacin
